Consolidated Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues	$ 2,523,912	$ 3,772,732
Cost of revenues	2,392,089	2,955,706
Gross profit	131,823	817,026
Research and development	3,161,326	1,947,205
Selling, general, and administrative	5,801,872	6,412,276
Operating Expenses	8,963,198	8,359,481
Operating loss	(8,831,375)	(7,542,455)
Other income (expense):
Other income, net	10,606	87,453
Interest expense	(43,560)	(524,118)
Nonoperating Income (Expense), Total	(32,954)	(436,665)
Loss from continuing operations before provision for income taxes and noncontrolling interests	(8,864,329)	(7,979,120)
Provision for income taxes	0	0
Net loss from continuing operations	(8,864,329)	(7,979,120)
Loss from discontinued operations - net	0	(1,227,748)
Net loss	(8,864,329)	(9,206,868)
Less - loss from continuing operations attributable to noncontrolling interests	(63,754)	(101,761)
Less - income from discontinued operations attributable to noncontrolling interests	0	243,026
Net loss attributable to NeoStem, Inc.	(8,800,575)	(9,348,133)
Preferred dividends	0	(107,844)
Amounts Attributable to NeoStem, Inc. common shareholders:
Loss from continuing operations	(8,800,575)	(7,877,359)
Loss from discontinued operations - net of taxes	0	(1,470,774)
Preferred dividends	0	(107,844)
Net loss attributable to NeoStem, Inc. common stockholders	$ (8,800,575)	$ (9,455,977)
Basic and diluted (loss) per share attributable to:
Continuing operations	$ (0.05)	$ (0.07)
Discontinued operations	$ 0.00	$ (0.01)
NeoStem, Inc. common stockholders	$ (0.05)	$ (0.08)
Weighted average common shares outstanding	166,988,970	111,806,949